More US Patients Choose Talk Therapy Over Psychotropics
METHODOLOGY:
Researchers analyzed data trends from four representative surveys of the US household population included in the 2018-2021 Medical Expenditure Panel Survey. They focused on nearly 18,000 adult outpatient mental health–related visits, including more than 6000 psychotherapy visits.
Psychotherapy or counseling was defined broadly as treatment for specific mental health disorders, primarily involving talk-based interaction between the patient and a mental health professional.
Participants received either psychotherapy alone, psychotropic medication alone, or both.
The fully adjusted analysis controlled for age, sex, and psychological distress measured using the Kessler-6 scale.
TAKEAWAY:
From 2018 to 2021, the use of psychotherapy without medications by adults receiving outpatient mental health care increased significantly (fully adjusted difference, 2.8%; 95% CI, 0.6%-5.0%), but the use of psychotropic medication alone declined (fully adjusted difference, −3.4%; 95% CI, −6.2% to −0.7%).
The mean number of psychotherapy visits per patient increased (adjusted difference, 2.1%; 95% CI, 0.6%-3.7%), with a significant increase noted among patients with mild or moderate distress.
Social workers and mental health counselors provided psychotherapy to an increased proportion of patients (adjusted difference, 17.7%; 95% CI, 13.0%-22.5%), whereas the involvement of psychiatrists decreased (adjusted difference, −6.7%; 95% CI, −11% to −2.4%).
Among patients receiving psychotherapy, treatment with anxiolytics/hypnotics decreased significantly (adjusted difference, −6.2%; 95% CI, −10% to −2.5%) as did treatment with antipsychotics (adjusted difference, −4.3%; 95% CI, −7.6% to −1%).
IN PRACTICE:
'After years of American mental health care moving toward greater use of psychiatric medications, the pendulum has started swinging back toward psychotherapy....Americans are becoming more willing to seek out and stick with psychotherapy,' lead author Mark Olfson, MD, MPH, College of Physicians and Surgeons, Columbia University and New York State Psychiatric Institute, New York City, said in a press release.
SOURCE:
The study was published online on May 1 in The American Journal of Psychiatry .
LIMITATIONS:
The study was limited by reliance on self-reported data, lack of diagnostic precision, and exclusion of important populations residing in institutional settings. It could not determine whether psychotherapy trends reflected changes in patients or practice. Additional limitations were the broad survey definition of psychotherapy, unmeasured treatment effectiveness, and lack of adjustment for multiple comparisons.
DISCLOSURES:
The investigators reported having no relevant conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the 'Company') (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August 4, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2025 at 8:00 AM ET / 2:00 PM CET. The call will include the Company's second quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-343-5172 International: +1-203-518-9856 Conference ID: CLLSQ2 Webcast Link: About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis' headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit and follow Cellectis on LinkedIn and X. TALEN® is a registered trademark owned by Cellectis. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@ Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@ Attachment 20250728_Q2 2025 earnings call announcement_ENGLISHError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
22 minutes ago
- Medscape
Medscape 2050: Adam Rodman
Medscape 2050: The Future of Medicine There will come a day, predicts Adam Rodman, MD, a general internist and medical educator at Beth Israel Deaconess Medical Center and assistant professor at Harvard Medical School, when AI systems change disease. That's the day when they can not only diagnose diseases more accurately than humans, but define diseases in ways that only machines can understand. Take heart attacks, for example. Rodman hopes cardiologists will forgive him for pointing out that AI can already detect blocked coronary arteries from an EKG in ways that humans can't. In the not-too-distant future, Rodman believes, medicine will begin redefining more diseases and treatments that are simply not understandable by the human brain. That day isn't here yet, Rodman explains, because today's AI systems are still pretty similar to us. 'They're trained on a human understanding of disease,' he says, 'so even the best models are following the guidelines that we give them.' They mimic human reasoning, albeit a lot faster and using a lot more data. But as new AI models develop, we could reach what Rodman calls 'a nonhuman nosology': our clinical reasoning vs a machines-only thought process. And what happens when those disagree? What does it mean — for both doctors and patients — to trust a computer that we can't understand? Is this the day when doctors are out of a job? Rodman doesn't think so. Because medicine is about more than computation. There are relationships and procedures that can't be replaced. But certain areas of clinical practice will certainly change. 'If you have a job where you can sit down at a computer and interpret most of the data that has already been collected for you to make a decision,' he says, you should start looking over your shoulder. Medicine is going through an 'epistemic shift,' Rodman says, where the parameters of how we think are changing, so it's hard to predict what will come next. But we should all get ready.
CNN
22 minutes ago
- CNN
Kennedy announces plan to reform Vaccine Injury Compensation Program
US Health and Human Services Secretary Robert F. Kennedy Jr. said Monday that he is working with the Justice Department to overhaul a national program that compensates people injured by vaccination. Kennedy, a longtime critic of the Vaccine Injury Compensation Program, wrote on X that he would 'fix' the VICP process, which he says 'has devolved into a morass of inefficiency, favoritism, and outright corruption.' Congress established the VICP in the 1980s as a route for people who have rare but serious side effects from vaccinations to receive compensation from pharmaceutical companies, without those manufacturers being found negligent. Kennedy has long argued that the program has ignored its mandate to quickly and fairly cover vaccine injury claims. The anti-vaccine group Children's Health Defense, which he chaired until last year, has filed multiple lawsuits against the government demanding records from VICP and federal databases of those claims. Kennedy said in his post Monday that the officials overseeing VICP, known as special masters, prioritize the finances of the federal health department's trust fund over those claims. Those special masters are appointed by the Court of Federal Claims and can be removed only by that court, 'exactly to give them independence and keep them out of politics,' Dorit Reiss, a professor of law at UC Law San Francisco, told CNN. This action 'serves a broader anti-vaccine agenda,' Reiss said. This new effort could open the door for HHS to bolster debunked theories that vaccines cause autism. It could also revive legal arguments around the safety of the HPV vaccine Gardasil, made by Merck. Kennedy, as a consultant for Wisner Baum prior to becoming health secretary, referred 'many hundreds' of cases to the law firm, including those claiming injury from Gardasil shots. Per the consulting agreement, Kennedy was entitled to 10% of any compensation payout, according to his financial disclosures. He pledged in written responses to senators to divest entirely from those lawsuits — which, he said, meant he would not need to recuse himself from decision making around Gardasil. In those responses, Kennedy said he divested any litigation interests to his 'non-dependent, adult son.' He did not name the son, but one of his four sons, Conor Kennedy, works for Wisner Baum. Kennedy has also argued that Covid-19 vaccine injury claims should be included in VICP; those claims, which numbered more than 13,000 by the end of 2024, are covered in a separate but similar program to cover injuries from countermeasures. Special masters found 3% of those claims eligible for compensation, according to the Government Accountability Office. The Children's Health Defense separately filed a lawsuit against HHS last week, arguing that it failed to establish a task force for safer childhood vaccines mandated in the 1980s. The suit also revives one of Kennedy's longtime claims, although the government did convene that task force and issue a report in 1998.
